Medical/Pharmaceuticals
Mr. Chong-Yoon Lim, Chairman of COREE Group emphasizes "Creative destruction and Healthcare 4.0" [New Year Message at X-Twitter SNS]
SEOUL, South Korea, Jan. 3, 2024 /PRNewswire/ -- Chong-Yoon Lim, Chairman of COREE group, President of Hanmi pharmaceutical company and Former Chairman of Korea Biotechnology Industry Organization (The largest shareholder group of Coree HK, Hanmi (KOSPI) and Dx&Vx (KOSDAQ), as well), highlighted ...
2024-01-03 22:00
2388
Turn Biotechnologies' Expanded eTurna™ Delivery Platform Designed to Solve Delivery and Targeting Issues that Challenge Industry
* Company announces development of novel ionizable lipids and stabilizing components * eTurna™ delivery platform expected to improve safety, reduce immunogenicity * Customizable platform can be optimized to treat variety of cells, tissues and organs * Platform can accommodate different rou...
2024-01-03 22:00
2199
Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer
DURHAM, N.C., and BEIJING, Jan. 3, 2024 /PRNewswire/ -- Brii Biosciences Limited
2024-01-03 20:00
5291
Ribo partners with Boehringer Ingelheim to develop new treatments for people with liver diseases
INGELHEIM, Germany, MÖLNDAL, Sweden and KUNSHAN, China, Jan. 3, 2024 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. and Ribocure AB (Ribo) today announced a collaboration with Boehringer Ingelheim to develop novel treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis...
2024-01-03 19:37
1839
Belief BioMed Successfully Completed Dosing of First Subject in the Registrational Clinical Trial for Hemophilia A
SHANGHAI, Jan. 3, 2024 /PRNewswire/ -- Belief BioMed Group (BBM), an industry-leading biotech company focusing on innovative gene therapies, announced the completion of first subject dosing in its registrational clinical trial (CTR20233400) of BBM-H803, a gene therapy for hemophilia A, independen...
2024-01-03 18:10
2079
Bangkok Dusit Medical Services strengthens partnership with CNN focusing on global health issues and solutions
HONG KONG, Jan. 3, 2024 /PRNewswire/ -- Bangkok Dusit Medical Services Public
Company Limited (BDMS), the largest private healthcare network inThailand, is
continuing its long-term partnership with CNN International Commercial (CNNIC)
through the sponsorship ofVital Signs
2024-01-03 11:30
2376
Sciwind Biosciences Announces Positive Topline Results from Phase 3 Clinical Trial of Ecnoglutide (XW003), a Long-acting cAMP Signaling Biased GLP-1 Analog, in Adult Patients with Type 2 Diabetes in China
* Study participants receiving 0.6 and 1.2 mg ecnoglutide once weekly for 24 weeks achieved HbA1c reductions of 1.96 and 2.43% from baseline, respectively, compared to 0.87 % for placebo * In the 1.2 mg ecnoglutide cohort, 76.1% of participants achieved HbA1c ≤ 6.5% and 35.2% achieved HbA1c< ...
2024-01-03 10:00
2558
WuXi XDC Enters into Partnership Agreement with IntoCell, Enabling Clients to Accelerate ADC Discovery and Development
SHANGHAI, Jan. 2, 2024 /PRNewswire/ -- WuXi XDC, a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the other types of bioconjugate market, and IntoCell, a Korean biotechnology company dedicated to developing novel ADC platform technologies, ...
2024-01-03 09:28
1815
Meihua International Medical Technologies Co., Ltd. Announces Closing of Initial $6 Million Tranche of Potential $50.5 Million Maximum Offering
YANGZHOU, China, Jan. 2, 2024 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (NASDAQ: MHUA), a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries inChina, today announced the closing of i...
2024-01-03 06:19
4498
Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca
NATICK, Mass., Jan. 2, 2024 /PRNewswire/ -- Allorion Therapeutics ("Allorion"), a US andChina-based biotechnology company that focuses on the discovery of new small molecule drugs for treating cancer and autoimmune diseases, has entered into an exclusive option and global license agreement with A...
2024-01-02 22:00
1973
MediLink Therapeutics Announces Worldwide Collaboration and License Agreement with Roche to develop next-generation antibody drug conjugate in Oncology
SUZHOU, China, Jan. 2, 2024 /PRNewswire/ -- MediLink Therapeutics ("MediLink"), announced today that it has entered into a worldwide collaboration and license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) on the development of a next-generation antibody-drug conjugate candidate YL211, targeti...
2024-01-02 22:00
1797
Novel Device Facilitates Successful No-Shave FUE Transplants for Long Hair with Ease
LOS ANGELES, Jan. 2, 2024 /PRNewswire/ -- A recent study published in the Clinical, Cosmetic and Investigational Dermatology journal reveals a groundbreaking advancement in hair transplantation, reports Dr U Hair and Skin Clinic. The research, titled "No-Shave Long Hair Follicular Unit Excision u...
2024-01-02 21:00
1772
YolTech Therapeutics to Present and Unveil Major Progress at Biotech Showcase 2024
SHANGHAI, Jan. 2, 2024 /PRNewswire/ -- YolTech Therapeutics, a biotech company developingin vivo gene editing therapies to treat rare genetic diseases, recently announced that it will present an overview of its technology and provide corporate updates on key programs at Biotech Showcase, taking p...
2024-01-02 20:30
1542
Pulnovo Medical Announces PADN Receives FDA HUD Designation and US CMS Medicare Coverage Code and NMPA Approval
SHANGHAI, Jan. 2, 2024 /PRNewswire/ -- Pulnovo Medical Limited, a globally recognized device pioneer in the treatment of Pulmonary Hypertension (PH) and Heart Failure (HF), recently announced that it has successfully obtained Humanitarian Use Device (HUD) designation from the US FDA and approval ...
2024-01-02 20:30
2177
Gannex Announces Positive Interim Results from 52-Week Phase II Clinical Trial of Once-Daily ASC41 Tablet in Patients with Biopsy-Confirmed Non-alcoholic Steatohepatitis
--Up to 68.2% mean relative reduction in liver fat content from baseline in biopsy-confirmed non-alcoholic steatohepatitis (NASH) patients receiving 12-week treatment of ASC41 tablet --At Week 12, up to 93.3% patients achieved at least a 30% relative reduction in liver fat content from baseline ...
2024-01-02 20:06
2764
Mabwell to attend 42nd JP Morgan Healthcare Conference and present at Biotech Showcase
SHANGHAI, Jan. 2, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that Dr.Hai Wu, President of R&D of Mabwell, will attend 42nd JP Morgan Healthcare Conference and present at Biotech Showcase in San Francisco, United State...
2024-01-02 17:15
1834
Ascentage Pharma to Present at 42nd J.P. Morgan Healthcare Conference
SUZHOU, China and ROCKVILLE, Md., Jan. 1, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it will attend the 42nd J.P. Morgan Healthcare ...
2024-01-02 11:58
1996
Xinhua Silk Road: Xinhua-Yushu Wild Cordyceps Sinensis Price Index unveiled in Beijing
BEIJING, Jan. 2, 2024 /PRNewswire/ -- The Xinhua-Yushu Wild Cordyceps Sinensis
Price Index was officially released on Dec. 27th inBeijing, capital of China,
indicating the accelerated development of wild cordyceps sinensis industry
towards a new stage of digital, information and modern mode.
2024-01-02 10:06
2502
Innovent Dosed First Participant in Phase 3 Clinical Study (GLORY-2) of Mazdutide (IBI362) Higher Dose 9 mg in Chinese Adults with Obesity
ROCKVILLE, Md. and SUZHOU, China, Jan. 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and o...
2024-01-02 08:00
9322
Demron by RST - Advanced Protection Against Today's Nuclear Threats
MIAMI, Jan. 2, 2024 /PRNewswire/ -- Radiation Shield Technologies (RST) proudly marks over two decades of innovation with Demron, a unique fabric designed to safeguard frontline personnel, including military, nuclear industry workers, emergency response teams, Hazmat Teams, firefighters, law enfo...
2024-01-02 08:00
2052
Week's Top Stories
Most Reposted
LONG AN INTERNATIONAL PORT JOINS 12TH PORTECH ASIA SUMMIT 2025 IN MALAYSIA
[Picked up by 337 media titles]
2025-01-18 03:30
Supported by the Luxembourg Government, The Luxembourg House of Financial Technology (LHoFT) and the Asian Development Bank (ADB) Announce the 2nd Edition of Catapult | SE Asia 2025
[Picked up by 313 media titles]
2025-01-22 15:38
Hong Kong Airlines Takes Off to Australia's Gold Coast Bringing Popular Travel Option for the Chinese New Year
[Picked up by 311 media titles]
2025-01-18 17:00
dss⁺ Announces Strategic Changes to Executive Leadership Team in Asia Pacific Accelerating growth and impact for high-hazard industries in the region
[Picked up by 309 media titles]
2025-01-21 16:00
HARD ROCK HOTEL BALI ACHIEVES PRESTIGIOUS GSTC CERTIFICATION
[Picked up by 306 media titles]
2025-01-20 14:27
Most Read
LONG AN INTERNATIONAL PORT JOINS 12TH PORTECH ASIA SUMMIT 2025 IN MALAYSIA
2025-01-18 03:30
12431
Hong Kong Airlines Takes Off to Australia's Gold Coast Bringing Popular Travel Option for the Chinese New Year
2025-01-18 17:00
11631
EZGO ANNOUNCES FINANCIAL RESULTS FOR FISCAL YEAR 2024
2025-01-18 06:45
8827
MONTECH Debuts the Heritage: A New Era of Leather Craft & High-End PC
2025-01-18 22:00
5503
